Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-25 02:02 UTC

BIOMED PULSE

Friday, July 25, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Ebola Bundibugyo virus disease outbreak in DRC and Uganda has now surpassed 2,124 confirmed cases and 828 deaths as of July 15, making it the dominant global health emergency of 2026. Mood: urgent on multiple fronts — Ebola accelerating, Cyclospora spreading, and WHO dementia guidelines offer a rare note of prevention optimism.

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS DISEASE — DRC AND UGANDA (PHEIC)

  • As of July 15, 2026, WHO reports 2,124 confirmed cases and 828 deaths from Bundibugyo virus disease (BVD) in DRC, with cross-border transmission continuing into Uganda. [1]
  • The case fatality rate among confirmed cases sits near 39%, a steep climb from 452 deaths recorded just two weeks earlier on July 1 when confirmed cases stood at 1,460. [2][1]
  • WHO declared BVD a Public Health Emergency of International Concern (PHEIC) on May 22, 2026, following the first detection of high-mortality illness in Mongbwalu Health Zone, Ituri Province, DRC on May 5. [3][4]
  • Africa CDC and WHO launched a joint continental Ebola response plan on June 5 seeking to raise US$518 million to support African countries at risk of spread. [5]
  • WHO issued its first comprehensive filovirus clinical management guidelines on June 17, covering all Ebola types and Marburg virus. [6]
  • The PARTNERS clinical trial opened patient enrolment in DRC on July 2 to identify the first effective treatments specifically for Bundibugyo virus disease. [7]
  • WHO added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing on July 2; the test identifies viral genetic material in blood samples for rapid confirmation. [8]
  • CDC has mobilized an international response and expanded enhanced airport screening from Washington-Dulles to Atlanta's Hartsfield-Jackson to intercept arriving travelers from affected regions. [9][10]

CYCLOSPORA OUTBREAK — TACO BELL ICEBERG LETTUCE, MULTISTATE USA

  • Shredded iceberg lettuce served at Taco Bell locations has been identified as the source of a Cyclospora cayetanensis outbreak sickening 1,644 people across five states as of July 17.
  • The outbreak expanded to four new states as of July 24, with CDC actively updating its cyclosporiasis response.
  • CDC held a telebriefing on its cyclosporiasis response on July 14, 2026, underscoring the breadth of the investigation.

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY

  • As of the fifth WHO Disease Outbreak News report on July 2, the Andes hantavirus (ANDV) outbreak linked to M/V Hondius cruise ship continues, with confirmed and suspected cases spanning multiple countries since first reported May 2.
  • The outbreak began when seven cases (two lab-confirmed ANDV, five suspected) were identified among 147 passengers and crew aboard the ship on May 4, 2026.
  • CDC provided a hantavirus response update on June 24, indicating continued active monitoring.

WEST NILE VIRUS — UNITED STATES

  • CDC warned on July 1 of an early and record West Nile virus season, urging Americans to use mosquito bite prevention measures during the July 4th holiday weekend.

NIPAH VIRUS — INDIA

  • WHO confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district, Kerala, India, on June 11, 2026, in an adult male who developed neurological symptoms on May 30.
  • A separate NiV case was confirmed in Bangladesh's Rajshahi Division in February 2026, also presenting with fever and neurological symptoms.

MPOX — RECOMBINANT STRAIN ALERT

  • WHO reported two cases of a recombinant monkeypox virus (MPXV) strain comprising genomic elements of both clade Ib and clade IIb in February 2026, a novel development arising from co-infection of the same individual with two related strains.

AVIAN INFLUENZA A(H9N2) — ITALY

  • WHO was notified on March 21, 2026 of a human A(H9N2) case in an adult male in Italy who had returned from Senegal, confirmed by next-generation sequencing.

MEASLES — BANGLADESH

  • As of April 4, 2026, Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases spanning 58 of 64 districts across all eight national divisions.

YELLOW FEVER — AMERICAS

  • From January 1 to May 26, 2026, six countries across the Americas reported 79 human yellow fever infections, carrying over from elevated 2025 transmission activity.

E. COLI — FROZEN BLUEBERRIES, USA

  • CDC issued a food safety alert on July 7, 2026 warning of an E. coli outbreak linked to recalled frozen blueberries; consumers are advised not to eat the recalled product.

🧬 LONGEVITY & AGING

WHO DEMENTIA PREVENTION GUIDELINES — UP TO 45% OF RISK MODIFIABLE

  • WHO released updated dementia risk-reduction guidelines on July 15, 2026, concluding that up to 45% of dementia cases could be prevented or delayed through evidence-based interventions across the life course.
  • The guidelines provide countries with actionable, population-level recommendations targeting modifiable risk factors including cardiovascular health, education, hearing loss, depression, and physical inactivity.
  • A Lancet Healthy Longevity commentary calls for urgent preparation for a "dementia prevention era," emphasizing that interventions must be designed for real-world populations with multiple comorbidities.

DELIRIUM AS A BRIDGE BETWEEN INFECTION AND DEMENTIA

  • Two separate Lancet Healthy Longevity papers propose that delirium following severe infection may be a key mechanistic link in the pathway to subsequent dementia, identifying it as an underrecognized risk marker in older adults.

NAD+ AND SENESCENT BONE REPAIR — SCAFFOLD STUDY

  • Researchers published findings in Bioactive Materials describing a hierarchical scaffold designed to restore NAD+ homeostasis and redox balance in aged bone tissue, directly targeting senescent metabolism to improve repair outcomes in older individuals.

TELOMERE REPAIR, PML BODIES, AND LAMIN B1 IN AGING CANCER CELLS

  • A study published July 23 in Nucleus examined repair and misrepair of telomeric DNA in dynamic interactions with PML nuclear bodies and lamin B1 in doxorubicin-treated cancer cells, illuminating how nuclear architecture influences genomic stability in aging-related cancer biology.

P16-INK4A SENESCENCE MARKER VALIDATION

  • Research published July 21 in Islets highlights the critical importance of antibody validation when detecting the senescence marker p16-INK4A by immunohistochemistry in pancreatic tissue, cautioning that unreliable detection could confound aging and diabetes research.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • Published July 16 in Annals of Medicine, researchers found that recombinant human collagen XVII protects epidermal stem cells from blue light-induced photoaging by downregulating the Notch signaling pathway, suggesting a topical or systemic anti-aging intervention target.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • A study in Toxicology Reports found that kaempferol, a flavonoid isolated from Moringa oleifera, increased longevity and reversed drug-induced functional senescence in Drosophila melanogaster, pointing to potential anti-aging properties of the compound — notable given simultaneous CDC alerts about Salmonella in moringa supplement products.

TAU, EMERIN, AND NUCLEAR MECHANOTRANSDUCTION IN NEURONS

  • Research published July 7 in Nucleus identified that tau-induced cytoskeletal remodeling in neurons elevates the mechanically-sensitive nuclear envelope protein emerin, linking nuclear mechanotransduction to tau pathology relevant to Alzheimer's disease and neurodegeneration.

HIGH-DOSE INFLUENZA VACCINE META-ANALYSIS IN OLDER ADULTS

  • A systematic review and meta-analysis in Lancet Healthy Longevity assessed high-dose versus standard-dose influenza vaccines in older adults, finding evidence for improved hospitalization and mortality outcomes with high-dose formulations — an actionable finding for the 65-plus population.

METABOLIC LIVER DISEASE AND TOBACCO — GLOBAL BURDEN TO 2038

  • A Europe PMC study covering 1990-2023 projects global trends in metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco through 2038, identifying tobacco exposure as a modifiable driver of a liver disease category strongly associated with accelerated aging.

💊 NEW CURES & APPROVALS

SCOMARA (SIROLIMUS) — AFT PHARMACEUTICALS LTD

  • AFT Pharmaceuticals received an original tentative approval (ORIG TA) from FDA for SCOMARA, an oral sirolimus formulation under NDA218528; sirolimus (an mTOR inhibitor) has established uses in transplant rejection and investigational longevity-adjacent applications.

JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORP

  • Incyte Corp received a supplemental approval (SUPPL AP) for JAKAFI XR, an extended-release formulation of the JAK1/JAK2 inhibitor ruxolitinib phosphate under NDA217180, used in myelofibrosis and graft-versus-host disease.

INREBIC (FEDRATINIB HYDROCHLORIDE) — BRISTOL-MYERS

  • Bristol-Myers received a supplemental approval for INREBIC (fedratinib hydrochloride, NDA212327), a JAK2 inhibitor indicated for myelofibrosis.

CANAGLIFLOZIN — TEVA PHARMACEUTICALS USA

  • Teva Pharmaceuticals USA received original approval (ORIG TA) for a canagliflozin generic under ANDA210451; canagliflozin is an SGLT2 inhibitor used in type 2 diabetes and heart failure, drug classes of growing interest in metabolic aging research.

CAMCEVI ETM (LEUPROLIDE MESYLATE) — ACCORD

  • Accord received a supplemental approval for CAMCEVI ETM (leuprolide mesylate, NDA219745), a GnRH agonist used in advanced prostate cancer and other hormone-sensitive conditions.

PITOLISANT HYDROCHLORIDE — NOVITIUM PHARMA

  • Novitium Pharma received original approval for a pitolisant hydrochloride generic (ANDA218495), an H3 receptor inverse agonist used in narcolepsy.

REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB

  • Bristol Myers Squibb received a supplemental approval for REVLIMID (lenalidomide, NDA021880), used in multiple myeloma and myelodysplastic syndromes.

🧪 CLINICAL TRIALS

PARKINSON'S DISEASE — VG081821AC ADENOSINE A2A RECEPTOR ANTAGONIST

  • A Phase IIb trial (NCT07725562) registered July 24, 2026 is evaluating oral VG081821AC tablets in patients with early to mid-stage Parkinson's disease; the drug blocks the adenosine A2A receptor to improve motor function without dyskinesia, a mechanism distinct from current dopaminergic therapies.

BUNDIBUGYO VIRUS DISEASE — PARTNERS TREATMENT TRIAL (DRC)

  • The PARTNERS clinical trial, sponsored in coordination with WHO, opened patient enrolment in DRC on July 2, 2026 to evaluate the first candidate therapeutics against Bundibugyo virus disease — a major milestone since no approved treatments currently exist for this Ebola subtype. [7]

DOUBLE-FILTRATION PLASMAPHERESIS FOR MICROPLASTICS AND PFAS REDUCTION

  • A prospective within-subject biomarker study (NCT07658443) is evaluating whether clinically prescribed double-filtration plasmapheresis (DFPP) reduces circulating microplastic, nanoplastic, and PFAS concentrations in peripheral blood in 20 participants — a novel environmental aging and toxicology trial.

PRECISION MEDICINE LAB COMMUNICATION FOR OLDER ADULTS

  • Trial NCT07391904, registered July 24, 2026, will test a personalized Electronic Health Record lab result communication tool for adults aged 65 and older, aiming to improve comprehension and clinical decision-making for aging patients compared to standard uniform lab reporting.

NEOADJUVANT RADIOTHERAPY PLUS TISLELIZUMAB, LIPOSOMAL IRINOTECAN, AND CAPECITABINE IN RECTAL CANCER

  • Trial NCT07104604 is evaluating the combination of radiotherapy, PD-1 inhibitor tislelizumab, liposomal irinotecan, and capecitabine in patients aged 18-75 with proficient mismatch repair (pMMR) locally advanced rectal adenocarcinoma, a population historically resistant to immunotherapy.

PLX038 IN CNS TUMORS WITH MYC/MYCN AMPLIFICATIONS

  • Trial NCT06161519, updated July 24, is studying PLX038 in primary central nervous system tumors harboring MYC or MYCN amplifications; approximately 30% of the roughly 90,000 annual US brain and spinal cord tumor diagnoses are malignant and associated with poor five-year survival.

ANTIRETROVIRAL DRUGS AND METABOLIC AGING IN HEALTHY VOLUNTEERS

  • Phase 2 trial NCT05652478 is investigating early metabolic effects of integrase strand transfer inhibitors (INSTIs) in healthy volunteers, seeking to understand mechanisms of INSTI-associated weight gain linked to diabetes and cardiovascular disease risk over time.

📢 PUBLIC HEALTH

WHO CANCER PROJECTION — CASES NEAR DOUBLING BY 2050

  • WHO warned on July 8, 2026 that new global cancer cases are projected to nearly double by 2050 from the current 20.6 million annually, with close to 10 million deaths per year already — more than 26,000 lives lost daily.

WHO DEMENTIA RISK GUIDELINES — 45% PREVENTABLE

  • WHO's July 15 dementia guidelines are directed at national governments and health systems, urging integration of cognitive health interventions into routine care beginning well before symptoms emerge.

GLOBAL CHILDHOOD IMMUNIZATION COVERAGE — 2025 WUENIC DATA

  • In 2025, 90% of infants globally (approximately 116 million) received at least one DTP dose and 85% (roughly 110 million) completed the full three-dose series, per the annual WHO-UNICEF Estimates of National Immunization Coverage.

EL SALVADOR ELIMINATES TRACHOMA

  • WHO validated El Salvador on July 13, 2026 as having eliminated trachoma as a public health problem; trachoma is the world's leading infectious cause of blindness.

WHO GLOBAL HUNGER REPORT — THIRD CONSECUTIVE YEAR OF DECLINE

  • The 2026 UN State of Food Security and Nutrition report shows global hunger declined for a third consecutive year in 2025, though improvements remain fragile, unevenly distributed, and insufficient to meet SDG targets by 2030.

CDC TRAVELER-BASED GENOMIC SURVEILLANCE SURPASSES ONE MILLION PARTICIPANTS

  • CDC's Traveler-Based Genomic Surveillance program surpassed one million voluntary air travel participants as of January 30, 2026, strengthening the agency's ability to detect emerging pathogens at borders.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026 to respond to New World Screwworm (Cochliomyia hominivorax), a parasitic fly whose larvae infest living tissue and which poses both animal and human health risk.

INFANT BOTULISM — NARA ORGANICS FORMULA RECALL

  • CDC urged parents on June 13, 2026 to immediately stop using all Nara Organics Whole Milk Organic Infant Formula linked to an ongoing infant botulism outbreak investigation.

This briefing is for informational purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  6. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  7. Patient enrolment begins in a scientific trial to identify the… — WHO News
  8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260725-02-v38 · 2026-07-25 02:02 UTC · pulse.uzylab.com

Read next